UPDATE : Monday, September 7, 2020
상단여백
Celltrion will use Oracle Health platform to streamline processes
Celltrion will use Oracle Health platforms to help streamline regulatory re...
by Marian Chu  |  2017-09-27 10:47
라인
Can Celltrion, Samsung make stable earnings with biosimilar?
Amid the intensifying competition to lower drug prices, market watchers pre...
by Nam Doo-hyun  |  2017-09-26 17:31
라인
Medifron aims high through R&D
Medifron said Friday that it would increase its capital by issuing new stoc...
by Lee Han-soo  |  2017-09-25 16:19
라인
Korea lags far behind in biomedical R&D: report
Korea’s investment in the biomedical research and development lags far behi...
by Nam Doo-hyun  |  2017-09-21 16:14
라인
Biosimilar prescriptions fall by the wayside in Korea
Biosimilar uptake in the Korean market has been dismal, according to data a...
by Marian Chu  |  2017-09-21 14:56
라인
Samsung Bioepis gets additional approval for its biosimilar
Amid the controversy caused by MSD Korea’s alleged decision to cease promot...
by Lee Hye-seon  |  2017-09-21 12:03
라인
MSD dissolves promotion team for Samsung Bioepis’ biosimilars
MSD Korea has dissolved its Samsung Bioepis’s biosimilar promotion team and...
by Lee Han-soo  |  2017-09-21 11:58
라인
Sillajen emerges as biggest beneficiary of preferential listing
Sillajen has emerged as the most successful case of the preferential listin...
by Nam Doo-hyun  |  2017-09-20 17:22
라인
Samsung Bioepis gets nods for phase 3 trials to treat macular degeneration
Samsung Bioepis said Tuesday that it has received Ministry of Food and Drug...
by Lee Han-soo  |  2017-09-19 17:39
라인
Korean biopharmaceutical industry ranked 2nd among emerging countries
The Korean biopharmaceutical industry ranked second only to Singapore regar...
by Marian Chu  |  2017-09-19 10:37
라인
EU approvals for Samsung Bioepis push up share prices
Investors are showing higher expectation for Samsung Bioepis, a Samsung Gro...
by Nam Doo-hyun  |  2017-09-18 14:45
라인
Genexin, Handok presents persistent growth hormone clinical trial results
Genexin and Handok have announced the intermediate results of phase 2 clini...
by Lee Han-soo  |  2017-09-18 14:39
라인
Celltrion in controversy over sexual harassment case
Celltrion found itself embroiled in a controversial situation afters CEO Se...
by Lee Han-soo  |  2017-09-15 18:11
라인
‘Knowledge’ is core ability for bio industrialists, survey says
“Knowledge” is the most important element for people engaged in bio and hea...
by Nam Doo-hyun  |  2017-09-15 16:28
라인
Access Bio, PFSCM sign supply agreement for malaria kit
Access Bio said Friday that it has signed a supply agreement of partnership...
by Lee Han-soo  |  2017-09-15 14:52
라인
‘BIOplus Incheon 2017’ shares product-developing know-how
BIOplus Incheon 2017 successfully finished their second annual global confe...
by Lee Han-soo  |  2017-09-14 11:14
라인
Medipost to commercialize new stem cell-culture tech
Medipost announced Wednesday that it has acquired a domestic patent for com...
by Constance Williams  |  2017-09-14 10:38
라인
Hanall Biopharma made $81-million technology export to China
Hanall Biopharma said Tuesday it has licensed out two new bio drugs under d...
by Lee Hye-seon  |  2017-09-13 13:23
라인
New VC investments in bio, medical fields fall sharpest in H1
New venture capital investments in bio and medical industries have fallen m...
by Nam Doo-hyun  |  2017-09-13 13:23
라인
Celltrion presents Herzuma’s clinical results in Europe
Celltrion said Friday that it has presented the results of the clinical saf...
by Lee Han-soo  |  2017-09-11 12:19
여백
여백
여백
Back to Top